NeoGenomics Reports Record Revenue of $76 Million with 17% Organic Revenue Growth in the Fourth Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
NeoGenomics (NEO) Tops Q4 EPS by 1c, Revenues Beat; Offers FY19 Revenue Guidance
February 19, 2019 7:09 AM ESTNeoGenomics (NASDAQ: NEO) reported Q4 EPS of $0.06, $0.01 better than the analyst estimate of $0.05. Revenue for the quarter came in at $76.5 million versus the consensus estimate of $71.43 million.
Consolidated revenue increased 24.5% to $76.5 millionConsolidated revenue increased 17.0% to $71.8 million, excluding GenoptixClinical Services revenue increased 23.3% to $65.9 millionPharma Services revenue increased 32.6% to $10.6 millionGross profit increased 38.7% to $37.1 millionGross margin increased approximately 500 basis... More